McKesson Extended Care Skin Protectant - quietly critical for US long-term care

By Julian Reed, ad hoc news B2B & Pro Desk. Reviewed July 04, 2026, 7:03 PM ET. Details in the imprint.

McKesson Extended Care Skin Protectant ointment sits in a squat white tube on the bedside cart, its blue label already smudged by gloved hands after a long shift. A nurse squeezes a pea-sized dot of the thick zinc-oxide cream, noting how it spreads smoothly and stays opaque on fragile skin.

What this McKesson ointment does

McKesson Extended Care Skin Protectant is a zinc-oxide based barrier ointment used to help prevent and treat moisture-associated skin damage in long-term care and home settings. It is part of McKesson’s private-label extended care line, marketed to nursing homes, hospitals, and home health agencies across the US. The ointment is typically formulated with 20% zinc oxide, petrolatum, and emollients to create a physical barrier against irritants like urine and feces, which are common drivers of incontinence-associated dermatitis in older patients.

A product sheet from McKesson describes the ointment as CHG-compatible, meaning it can be used alongside chlorhexidine gluconate bathing without degrading the antimicrobial properties, a detail hospital infection-control teams care about. The same documentation notes that the ointment is dye-free and fragrance-free to reduce the risk of contact irritation in patients with sensitive or compromised skin. The tube format is offered in multiple sizes, often around 4 oz, which balances ease of use on the unit with cost control for purchasing departments. Buyers typically order the ointment by the case through McKesson’s medical-surgical distribution catalog.

US availability and pricing reality

McKesson distributes the Extended Care Skin Protectant all over the US through its medical-surgical channel and online ordering platforms for providers. Individual pricing is not typically advertised to consumers, because the ointment is purchased business-to-business by facilities, often under negotiated contracts. However, public catalog snapshots and third-party medical supply sites show case pricing that translates roughly to single-tube costs in the 2 to 5 dollar range, depending on formulation and case volume. In practice, a director of nursing signs off on a formulary choice, and supply chain managers place recurring orders to stock carts and in-room cabinets.

Because it is a private-label product, McKesson can position the ointment as a lower-cost alternative to branded barrier creams, while still controlling quality specifications and regulatory compliance. For US investors, that private-label positioning matters: margins on consumables like ointments and creams can be higher than on branded equivalents, especially when volume is steady and patient counts are predictable. The ointment is not something patients ask for by name, but procurement teams know the line and order it alongside gloves, underpads, and wound dressings. The result is a relatively stable, recurring revenue stream tied to aging demographics and chronic care needs.

Why caregivers choose a zinc barrier

Talk to someone like Lisa, a veteran wound care nurse in Ohio, and she will tell you that not all barrier creams behave the same when you are cleaning a patient for the fifth time in a night. She looks for a product that stays put, does not sting, and does not crumble into flakes on the patient’s skin. Zinc-oxide ointments like McKesson Extended Care Skin Protectant meet that practical checklist: the cream is thick but spreadable, and once applied, it forms an even, white film that can be gently wiped away without excessive friction. That tactile behavior is a big part of why these products endure in formularies.

From a clinical standpoint, incontinence-associated dermatitis is both common and costly in long-term care facilities, with studies showing prevalence rates over 30 percent in some cohorts. Prevention is cheaper than treatment: keeping moisture off the skin reduces the risk of breakdown, infection, and eventually pressure injuries, which can trigger regulatory scrutiny and malpractice exposure. A reliable barrier ointment becomes a small but strategic line item in care protocols. The Centers for Medicare & Medicaid Services (CMS) and state regulators do not specify brand names, but they expect facilities to have effective skin protection routines in place. McKesson’s ability to supply a house-label product that meets those routines strengthens its anchor position with US providers.

In terms of ingredients, zinc oxide is widely used in diaper creams and barrier products because it is inert, physically blocks irritants, and has a long record of safety in topical use. Petrolatum and additional emollients help keep the skin flexible, while creating the occlusive layer that traps moisture in the stratum corneum but prevents external fluids from direct contact. For infection-control teams, CHG compatibility means the ointment does not neutralize the antiseptic effect of chlorhexidine baths, which have become standard in many hospitals to reduce central line-associated bloodstream infections. McKesson’s product documentation emphasizes that compatibility because it supports institutional protocols rather than forcing trade-offs.

How it fits into McKesson’s business model

McKesson is widely known as one of the largest pharmaceutical and medical-surgical distributors in North America, but its private-label products like Extended Care Skin Protectant show another side of the model. Instead of simply reselling third-party brands, McKesson sources and brands its own line of consumables, from gloves to dressings to skin care items. These items typically sit in standardized planograms for facilities, often co-located in supply closets with McKesson-branded boxes and bottles. The extended care sub-brand is designed to target nursing homes, rehabilitation centers, and home health agencies, where recurrent, low-profile items make up a meaningful share of daily spend.

Chief executive Brian Tyler has highlighted in past earnings calls that medical-surgical solutions and private-label offerings contribute to segment margin resilience. While individual products like a zinc barrier ointment are small in dollar terms, they accumulate because they are used on virtually every incontinence-prone patient. As long-term care facilities pursue cost containment, private-label offerings from a trusted distributor provide a way to simplify vendors without sacrificing clinical basics. That can favor McKesson stock in the eyes of investors who look for predictable cash flows from non-glamorous, recurring categories instead of betting solely on blockbuster drugs.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.